000922638 000__ 03141cam\a2200445Ii\4500
000922638 001__ 922638
000922638 005__ 20230306150847.0
000922638 006__ m\\\\\o\\d\\\\\\\\
000922638 007__ cr\cn\nnnunnun
000922638 008__ 190917s2020\\\\sz\\\\\\o\\\\\000\0\eng\d
000922638 019__ $$a1121094595
000922638 020__ $$a9783030237653$$q(electronic book)
000922638 020__ $$a3030237656$$q(electronic book)
000922638 020__ $$z9783030237646
000922638 0247_ $$a10.1007/978-3-030-23765-3$$2doi
000922638 035__ $$aSP(OCoLC)on1119720863
000922638 035__ $$aSP(OCoLC)1119720863$$z(OCoLC)1121094595
000922638 040__ $$aGW5XE$$beng$$erda$$epn$$cGW5XE$$dUKMGB$$dOCLCF$$dOKS$$dN$T
000922638 049__ $$aISEA
000922638 050_4 $$aRC271.I45$$bC87 2020eb
000922638 08204 $$a616.99/406$$223
000922638 24500 $$aCurrent immunotherapeutic strategies in cancer /$$cMatthias Theobald, editor.
000922638 264_1 $$aCham :$$bSpringer,$$c[2020]
000922638 264_4 $$c©2020
000922638 300__ $$a1 online resource.
000922638 336__ $$atext$$btxt$$2rdacontent
000922638 337__ $$acomputer$$bc$$2rdamedia
000922638 338__ $$aonline resource$$bcr$$2rdacarrier
000922638 4901_ $$aRecent results in cancer research,$$x0080-0015 ;$$vvolume 214
000922638 5050_ $$aCurrent Development of Monoclonal Antibodies in Cancer Therapy -- Clinical Experience with Bispecific T-Cell Engagers -- Advances and challenges of CAR-modified T cells in clinical trials -- Targeting Cancer with Genetically Engineered TCR-T Cells -- Tailored Vaccines Based on Patient's Cancer Mutanome -- Next-Generation Checkpoint Inhibitors and Immune Agonists.
000922638 506__ $$aAccess limited to authorized users.
000922638 520__ $$aThis book offers a comprehensive review of recent advances in cancer immunotherapy, and explores the value and limitations of the most effective current therapeutic strategies and emerging treatment modalities. It discusses in detail the successes achieved using monoclonal antibodies (mAbs), including developments with regard to conjugated mAbs and also bispecific mAbs as novel treatment options for leukemia and solid tumors. It also examines the advances toward personalized immunotherapy, focusing on the effectiveness of adoptive cell therapy using genetically engineered T cells with tumor-associated antigen-specific T-cell receptors and chimeric antigen receptors, as well as the role of tailored vaccines based on the patient's cancer mutanome. Further, it describes the impressive therapeutic results recently achieved with checkpoint inhibitors, and analyzes novel strategies to modulate the immunosuppressive tumor microenvironment. Written by leading international experts and providing up-to-date information on emerging strategies, such as oncolytic virus-based therapy, epigenetic therapy, and combination therapy, the book appeals to all those with an interest in immunotherapy as it comes of age.
000922638 588__ $$aOnline resource; title from PDF title page (SpringerLink, viewed September 17, 2019).
000922638 650_0 $$aCancer$$xImmunotherapy.
000922638 7001_ $$aTheobald, Matthias,$$eeditor.
000922638 830_0 $$aRecent results in cancer research ;$$v214.
000922638 852__ $$bebk
000922638 85640 $$3SpringerLink$$uhttps://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-3-030-23765-3$$zOnline Access$$91397441.1
000922638 909CO $$ooai:library.usi.edu:922638$$pGLOBAL_SET
000922638 980__ $$aEBOOK
000922638 980__ $$aBIB
000922638 982__ $$aEbook
000922638 983__ $$aOnline
000922638 994__ $$a92$$bISE